About this trial
Transthoracic ultrasonographic assessment of the diaphragmatic performance as a predictor for the outcome of NIV in critically ill COPD patients with acute exacerbation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
One Hundred fifty five critically ill COPD patients admitted to respiratory intensive care unit
Diagnosis of COPD and COPD exacerbation is fulfilled according to GOLD 2022 criteria
Age>40years
Disqualifiers
Age ˂ 40 years.
Refusal to participate in the study.
Patients with morbid obesity (BMI>40).
Absolute indication for intubation like coma ,hemodynamic instability, or life threatening arrhythmia.
Trial population
COPD patients admitted to respiratory intensive care unit with acute exacerbation
Trial design
Cohort
Prospective
Treatments tested in this trial
transthoracic ultrasound
Other interventionThe following parameters will be assessed by TUS: Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )
Treatment groups
Trial outcomes
Primary outcomes
ultrasonographic assessement of COPD patients
To assess the diaphragmatic performance by transthoracic ultrasound in critically ill COPD patients with acute exacerbation
Secondary outcomes
Time saving
To estimate: * In hospital mortality. * Length of ICU stay. * Length of hospital stay.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: